美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Ultra納斯達克生物科

113.90

+4.924.51%

盤後：113.90-0.00310.00%18:23 EDT

成交量：4,211

成交額：47.65萬

市值：9,567.86萬

市盈率：- -

高：113.95

開：112.60

低：112.60

收：108.99

52周最高：126.40

52周最低：55.34

股本：84.00萬

流通股本：84.00萬

量比：0.52

換手率：0.50%

股息：0.33

股息率：0.29%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

吉利德科學擴大六項免許可費自願授權協議，力推每年一次HIV預防藥Lenacapavir

Sling Therapeutics 籌集 1.23 億美元，用於推進甲狀腺相關眼病藥物的研發

百時美施貴寶就安進擬推出的Opdivo生物類似藥提起訴訟

百時美施貴寶就奧普迪沃擬推出的生物類似藥起訴安進

吉利德科學攜手巴西衞生部，共促Lenacapavir本地化生產新篇章

吉利德科學：持續探索與泛美衞生組織合作，助力各國準備好並擴大長效艾滋病預防措施的普及

吉利德科學公司高管在電話會議上表示，HIV藥物市場的增長預計將在未來幾個季度內迴歸至2%至3%的正常水平。

吉利德與泛美衞生組織就拉丁美洲和加勒比地區艾滋病預防藥物獲取問題達成一致

吉利德科學攜手泛美衞生組織，加速拉美及加勒比地區HIV預防藥物Lenacapavir的可及性

吉利德高管表示，未來幾個季度HIV市場增長或將回歸2%-3%常態水平

吉利德高管透露：周服HIV預防藥物有望2027年第一季度上市

阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。

又爆了！集體飆漲！中東，再傳重磅

安進（AMGN）聯合療法III期臨床達主要終點

安進-阿斯利康肺癌聯合用藥在後期臨床試驗中顯著提升生存率

市場風向標：安進股價遭受重創

Assembly Biosciences有望獲得高達2.8億美元里程碑付款及美國境外特許權使用費

Assembly Biosciences旗下Gs-1179預計2026年底前將推進至生殖器皰疹二期臨床試驗階段

Assembly Biosciences：吉利德獨享HSV HPI項目臨床開發與商業化權利

Assembly Biosciences行使與吉利德關於HSV解旋酶-引物酶抑制劑項目的美國利潤分成選擇權

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BIB/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIB\",,,,,undefined,":{"symbol":"BIB","market":"US","secType":"STK","nameCN":"Ultra納斯達克生物科","latestPrice":113.9031,"timestamp":1789675200000,"preClose":108.9876,"halted":0,"volume":4211,"hourTrading":{"tag":"盘后","latestPrice":113.9,"preClose":113.9031,"latestTime":"18:23 EDT","volume":345,"amount":39498.2565,"timestamp":1789683822555,"change":-0.0031,"changeRate":-0.000027,"amplitude":0.017647},"delay":0,"changeRate":0.04510146108364616,"floatShares":840000,"shares":840000,"eps":0,"marketStatus":"盤後交易","change":4.9155,"latestTime":"09-17 18:54:13 EDT","open":112.6,"high":113.95,"low":112.6,"amount":476514.19129,"amplitude":0.012387,"askPrice":117.56,"askSize":127,"bidPrice":109.98,"bidSize":136,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789689600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":108.9876,"sharesOutstanding":1040000,"nav":108.5525,"aum":91184100,"dividendRate":0.002871,"bidAskSpread":0.002695,"preHourTrading":{"tag":"盘前","latestPrice":107.01,"preClose":108.9876,"latestTime":"08:07 EDT","volume":8,"amount":856.08,"timestamp":1789646849130,"change":-1.9776,"changeRate":-0.018145,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":113.9,"preClose":113.9031,"latestTime":"18:23 EDT","volume":345,"amount":39498.2565,"timestamp":1789683822555,"change":-0.0031,"changeRate":-0.000027,"amplitude":0.017647},"volumeRatio":0.524226,"impliedVol":0.4901,"impliedVolPercentile":0.7729},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIB\",,,,,undefined,":{"symbol":"BIB","floatShares":840000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.524226,"shares":840000,"dividePrice":0.327,"high":113.95,"amplitude":0.012387,"preClose":108.9876,"low":112.6,"week52Low":55.34,"pbRate":"--","week52High":126.399,"institutionHeld":0,"latestPrice":113.9031,"committee":0.034221,"eps":0,"divideRate":0.002871,"volume":4211,"delay":0,"ttmEps":0,"open":112.6,"prevYearClose":79.7794,"prevWeekClose":109.7741,"prevMonthClose":116.5968,"prevQuarterClose":100.74,"fiveDayClose":109.5953,"twentyDayClose":126.2177,"sixtyDayClose":89.7431},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BIB\",params:#limit:5,,,undefined,":[{"date":"2026-03-25","symbol":"BIB","amount":0.00714,"announcedDate":"2026-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-25","defaultRemindTime":1774445400000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-31","payableDate":"2026-03-25","currency":"USD","dateTimestamp":1774411200000,"payDate":"2026-03-31"},{"date":"2025-12-24","symbol":"BIB","amount":0.134637,"announcedDate":"2025-12-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-24","defaultRemindTime":1766586600000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-31","payableDate":"2025-12-24","currency":"USD","dateTimestamp":1766552400000,"payDate":"2025-12-31"},{"date":"2025-09-24","symbol":"BIB","amount":0.180541,"announcedDate":"2025-09-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-24","defaultRemindTime":1758720600000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-24","currency":"USD","dateTimestamp":1758686400000,"payDate":"2025-09-30"},{"date":"2025-06-25","symbol":"BIB","amount":0.170576,"announcedDate":"2025-06-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-25","defaultRemindTime":1750858200000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-25","currency":"USD","dateTimestamp":1750824000000,"payDate":"2025-07-01"},{"date":"2025-03-26","symbol":"BIB","amount":0.130939,"announcedDate":"2025-03-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-26","defaultRemindTime":1742995800000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-26","currency":"USD","dateTimestamp":1742961600000,"payDate":"2025-04-01"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BIB\",market:\"US\",,,undefined,":[{"executeDate":"2022-12-22","recordDate":"2022-12-23","paymentDate":"2022-12-30","value":0.019852,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-28","value":0.038393,"currency":"USD"},{"executeDate":"2024-03-20","recordDate":"2024-03-21","paymentDate":"2024-03-27","value":0.040324,"currency":"USD"},{"executeDate":"2024-06-26","recordDate":"2024-06-26","paymentDate":"2024-07-03","value":0.26476,"currency":"USD"},{"executeDate":"2024-09-25","recordDate":"2024-09-25","paymentDate":"2024-10-02","value":0.15285,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BIB\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1164691459","title":"吉利德科學擴大六項免許可費自願授權協議，力推每年一次HIV預防藥Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=1164691459","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164691459?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 20:31","pubTimestamp":1789561872,"startTime":"0","endTime":"0","summary":"吉利德科学宣布，扩大其六项免许可费的自愿授权协议，覆盖其每年仅需注射一次的HIV预防药物Lenacapavir。此举旨在拓宽药物可及性，助力全球抗击艾滋病疫情。通过这一系列协议，吉利德希望加快该长效预防方案在中低收入国家的推广，以应对持续存在的公共卫生挑战。该举措不仅彰显了公司在全球健康公平方面的承诺，也为实现2030年终结艾滋病流行的目标注入新动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU0289739699.SGD","GILD","BK4578","BIB","LU0889565916.HKD","IE00B7SZLL34.SGD","BK4550","LU1430594728.SGD","LU1674673428.USD","LU2089984988.USD","LU0823416689.USD","LU2324357040.USD","LU1023059063.AUD","LU1585245621.USD","TMED","LU1037948541.HKD","LU1066053197.SGD","BK4139","MEDI","SG9999015986.USD","IE00B19Z3B42.SGD","LU1934455277.USD","LU0965509101.SGD","LU2087621335.USD","BK4568","IBBQ","IE00BSNM7G36.USD","LU2468319806.SGD","SG9999015978.USD","LU0965509010.AUD","LU1057294990.SGD","LU0109394709.USD","IE0002270589.USD","BK4532","LU0859254822.USD","LU1066051498.USD","BK4585","BMED","LU0861579265.USD","LU2357627491.SGD","SG9999015945.SGD","LU0965509283.SGD","LU0234570918.USD","IE00B19Z3581.USD","BBH","LU0965508806.USD","LU0320765992.SGD","IBB","LU1571399168.USD","IE00BKVL7J92.USD","LU1778281490.HKD","LU2112291526.USD","IE00B3T34201.USD","LU1934455194.USD","BK4566","LU0122379950.USD","LU1674673691.USD","LU1839511570.USD","TBXU","IE00BZ1G4Q59.USD","LU0114720955.EUR","LU1037948897.HKD","SG9999015952.SGD","BK4583","BK4588","LU0058720904.USD","LU1061106388.HKD","LU1934455863.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667074086","title":"Sling Therapeutics 籌集 1.23 億美元，用於推進甲狀腺相關眼病藥物的研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2667074086","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667074086?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 19:01","pubTimestamp":1789556485,"startTime":"0","endTime":"0","summary":"Sling Therapeutics 筹集 1.23 亿美元，用于推进甲状腺相关眼病药物的研发Kunal Das/Siddhi Mahatole路透9月16日-药物研发公司Sling Therapeutics周三表示，已筹集1.23亿美元，用于推进其用于治疗甲状腺眼病的实验性口服药物的后期临床试验。该疾病会导致眼周发炎和肿胀，进而可能引发眼球突出和视力丧失。作为此次融资协议的一部分，Sling还任命了Forbion的Regina Salvat和Sectoral Asset Management的Franois Beaubien加入其董事会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nL4T4580NN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRDN","BK4599","IE00B4R5TH58.HKD","LU2242646821.SGD","PJP","BK4566","LU1057294990.SGD","TBXU","LU1061106388.HKD","LU0122379950.USD","LU0058720904.USD","BK4588","LU0109394709.USD","LU0289739699.SGD","PBE","IE00BJT1NW94.SGD","BK4139","LU2112291526.USD","BBH","BK4585","IBB","IE00BFTCPJ56.SGD","BK4533","IE00B2B36J28.USD","BK4581","LU0320765992.SGD","IE0002141913.USD","LU1571399168.USD","LU1983299246.USD","BIB","SG9999001440.SGD","AMGN","LU2089984988.USD","LU0889565916.HKD","BK4534","LU2242652126.USD","LU1023059063.AUD","IE00BJJMRZ35.SGD","IBBQ","LU0868494617.USD","IE0009355771.USD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667267605","title":"百時美施貴寶就安進擬推出的Opdivo生物類似藥提起訴訟","url":"https://stock-news.laohu8.com/highlight/detail?id=2667267605","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667267605?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 10:15","pubTimestamp":1789524901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2322448957.HKD","LU0058720904.USD","LU0320765992.SGD","AMGN","LU0109394709.USD","LU1236620834.HKD","BMY","LU1670711123.USD","PPH","LU0868494617.USD","LU1023059063.AUD","LU2272731600.USD","BK4566","LU1983299246.USD","IHE","BK4139","BK4559","LU2125154778.USD","LU0061475181.USD","BK4585","LU0289739699.SGD","BK4533","IE00BSNM7G36.USD","LU2272731865.HKD","PBE","LU1883839398.USD","XPH","IE0009355771.USD","LU0225284248.USD","LU0225771236.USD","LU1989771016.USD","TBXU","BK4534","LU0114720955.EUR","IBB","LU1868837300.USD","FTXH","BBH","LU1236620750.USD","LU1992135399.USD","LU2473716301.USD","LU2468319806.SGD","BIB","BK4588","IE00B4R5TH58.HKD","LU1868836591.USD","LU1868836757.USD","IBBQ","LU1261432733.SGD","PJP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667629132","title":"百時美施貴寶就奧普迪沃擬推出的生物類似藥起訴安進","url":"https://stock-news.laohu8.com/highlight/detail?id=2667629132","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667629132?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 01:29","pubTimestamp":1789493363,"startTime":"0","endTime":"0","summary":"百时美施贵宝就奥普迪沃拟推出的生物类似药起诉安进Blake Brittain路透9月15日-百时美施贵宝公司和小野制药公司已在特拉华州联邦法院起诉安进公司，试图阻止安进公司在美国推出其畅销癌症免疫疗法药物“欧迪沃”的生物类似药。百时美施贵宝和小野制药的发言人尚未立即回应置评请求。共同开发“欧狄沃”的百时美施贵宝和小野制药指控，安进的生物类似药将侵犯该药物所涉及的七项美国专利，并请求法院在专利有效期内禁止该生物类似药的销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nL4T4571DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0432979614.USD","LU2089984988.USD","LU0096364046.USD","BK4585","LU2125154935.USD","LU0321505439.SGD","LU0122379950.USD","PJP","LU1061106388.HKD","LU1093756168.USD","LU1868837136.USD","LU0267386448.USD","LU1868836591.USD","LU1093756325.SGD","IE0002141913.USD","LU1670711123.USD","LU0306807586.USD","LU1057294990.SGD","LU1718418525.SGD","LU2125154778.USD","BK4532","BMY","BK4599","SG9999001440.SGD","LU1868836757.USD","LU2242652126.USD","LU2596442595.SGD","LU1291159041.SGD","LU2242646821.SGD","LU1323610961.USD","LU0289739699.SGD","LU1074936037.SGD","LU1989771016.USD","LU1868836914.USD","PBE","IBB","LU1670711040.USD","LU1571399168.USD","LU0114720955.EUR","LU0306806265.USD","IHE","LU0225771236.USD","LU1868837300.USD","IE00B2B36J28.USD","LU1670710661.SGD","LU2360032135.SGD","LU1261432733.SGD","LU0985481810.HKD","LU1236620750.USD","LU1023059063.AUD","LU2133065610.SGD","LU1670710588.SGD","IBBQ","LU1983299246.USD","BK4534","LU0882574055.USD","LU2112291526.USD","LU0889565916.HKD","LU0058720904.USD","LU0321505868.SGD","IE00BJJMRZ35.SGD","LU0320765992.SGD","BK4139","BK4566","LU2468319806.SGD","LU0225284248.USD","LU0456855351.SGD","BK4533","LU1585245621.USD","BK4559","LU0237698245.USD","IE00BSNM7G36.USD","LU1430594728.SGD","04332","TBXU","BK4007","AMGN","IE00BFTCPJ56.SGD","LU1032466523.USD","BBH","LU1883839398.USD","BK4588","LU0061475181.USD","BIB","LU0109394709.USD","FTXH","IE00BFXG1179.USD","IE00B4R5TH58.HKD","LU1236620834.HKD","LU0868494617.USD","IE00BJT1NW94.SGD","IE0009355771.USD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120765496","title":"吉利德科學攜手巴西衞生部，共促Lenacapavir本地化生產新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=1120765496","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120765496?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:15","pubTimestamp":1789485331,"startTime":"0","endTime":"0","summary":"吉利德科学公司近日透露，正积极与巴西卫生部探索合作良机，旨在助力该国实现Lenacapavir药物的本土生产愿景。这一举措，无疑为巴西医药产业自主化进程注入了强劲动力。据悉，双方的洽谈聚焦于如何深化协作，以切实推进巴西卫生部既定的战略目标——即构建并强化Lenacapavir的本地制造能力。Lenacapavir，作为一款备受瞩目的长效抗逆转录病毒药物，其本地化生产若能落地，对巴西乃至更广泛地区的HIV防治工作意义深远。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0859254822.USD","SG9999015952.SGD","BIB","BK4550","LU1585245621.USD","BK4568","BMED","LU0882574055.USD","LU1061106388.HKD","LU1934455194.USD","BK4566","LU1934455277.USD","SG9999015978.USD","TMED","LU0823416689.USD","LU0861579265.USD","BK4585","LU2087621335.USD","LU0965509283.SGD","LU1023059063.AUD","LU0889565916.HKD","LU1839511570.USD","LU1674673428.USD","BK4532","LU0058720904.USD","LU2468319806.SGD","IBB","IE00B7SZLL34.SGD","LU1934455863.HKD","LU0122379950.USD","LU0965509010.AUD","LU1430594728.SGD","SG9999015945.SGD","BK4139","LU1037948897.HKD","LU2324357040.USD","LU2357627491.SGD","MEDI","LU0965509101.SGD","LU1674673691.USD","LU2112291526.USD","LU0114720955.EUR","BK4588","LU1778281490.HKD","IE00B19Z3B42.SGD","LU1037948541.HKD","TBXU","IE0002270589.USD","LU1066053197.SGD","LU0965508806.USD","BBH","IBBQ","BK4583","LU1571399168.USD","GILD","LU1057294990.SGD","SG9999015986.USD","LU1066051498.USD","LU0289739699.SGD","IE00B3T34201.USD","LU0320765992.SGD","LU2089984988.USD","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD","LU0109394709.USD","LU0234570918.USD","BK4578","IE00B19Z3581.USD","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158863992","title":"吉利德科學：持續探索與泛美衞生組織合作，助力各國準備好並擴大長效艾滋病預防措施的普及","url":"https://stock-news.laohu8.com/highlight/detail?id=1158863992","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158863992?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:15","pubTimestamp":1789485330,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）宣布，将继续探索与泛美卫生组织（PAHO）的合作机会，以支持各国做好充分准备，并推动长效艾滋病预防手段的可及性扩展。这一举措旨在强化全球公共卫生应对体系，尤其是针对中低收入国家的需求，通过技术转移、能力建设及供应链优化等途径，加快长效预防方案的落地与规模化应用。双方的合作重点在于应对实施层面的挑战，确保相关资源能够高效、公平地分配至最需要的人群，从而在更大范围内遏制HIV的传播。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673428.USD","LU1066053197.SGD","IE00B19Z3581.USD","LU0861579265.USD","LU1571399168.USD","LU1674673691.USD","SG9999015952.SGD","LU1430594728.SGD","IE00B7SZLL34.SGD","MEDI","IE00BSNM7G36.USD","LU1839511570.USD","IBBQ","TMED","LU1778281490.HKD","BK4583","IE00B19Z3B42.SGD","BBH","LU2468319806.SGD","TBXU","LU1057294990.SGD","IE00BZ1G4Q59.USD","LU0965509101.SGD","LU1061106388.HKD","LU1066051498.USD","LU0320765992.SGD","IBB","LU1037948541.HKD","BK4578","LU2112291526.USD","LU0058720904.USD","SG9999015978.USD","IE00BKVL7J92.USD","BK4566","BMED","LU0965508806.USD","LU0965509283.SGD","LU1023059063.AUD","LU1585245621.USD","LU1934455194.USD","LU0114720955.EUR","BIB","LU0859254822.USD","LU0889565916.HKD","LU0882574055.USD","BK4585","LU0965509010.AUD","BK4550","LU2089984988.USD","LU0122379950.USD","BK4139","BK4568","IE00B3T34201.USD","LU0109394709.USD","LU0234570918.USD","SG9999015986.USD","LU2357627491.SGD","LU1934455277.USD","LU1037948897.HKD","LU0289739699.SGD","LU2087621335.USD","LU1934455863.HKD","BK4532","LU2324357040.USD","LU0823416689.USD","IE0002270589.USD","GILD","SG9999015945.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667623020","title":"吉利德科學公司高管在電話會議上表示，HIV藥物市場的增長預計將在未來幾個季度內迴歸至2%至3%的正常水平。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667623020","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667623020?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:11","pubTimestamp":1789485099,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00B7SZLL34.SGD","LU2324357040.USD","LU1037948541.HKD","LU1061106388.HKD","GILD","LU0114720955.EUR","IE00B19Z3581.USD","LU0889565916.HKD","BK4566","TMED","LU0122379950.USD","LU0058720904.USD","BK4139","BBH","LU0320765992.SGD","LU1585245621.USD","LU0882574055.USD","LU1066053197.SGD","LU1066051498.USD","SG9999015945.SGD","IBB","LU0965509283.SGD","LU1430594728.SGD","LU0965509101.SGD","BK4550","BK4568","LU0289739699.SGD","LU1674673691.USD","BK4588","LU1037948897.HKD","LU1057294990.SGD","IBBQ","LU1934455863.HKD","BMED","LU1934455277.USD","IE0002270589.USD","TBXU","LU0234570918.USD","MEDI","LU1839511570.USD","LU0965509010.AUD","BK4532","SG9999015978.USD","LU1674673428.USD","BIB","IE00B19Z3B42.SGD","SG9999015952.SGD","LU0859254822.USD","IE00BKVL7J92.USD","LU2112291526.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667062306","title":"吉利德與泛美衞生組織就拉丁美洲和加勒比地區艾滋病預防藥物獲取問題達成一致","url":"https://stock-news.laohu8.com/highlight/detail?id=2667062306","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667062306?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:10","pubTimestamp":1789485029,"startTime":"0","endTime":"0","summary":"吉利德与泛美卫生组织就拉丁美洲和加勒比地区艾滋病预防药物获取问题达成一致路透9月15日-美国制药公司吉利德科学GILD.O周二表示，已与泛美卫生组织达成协议，将在拉丁美洲和加勒比地区扩大其艾滋病预防药物的可及性，以帮助这些地区遏制新发感染。吉利德公司指出，2010年至2024年间，拉丁美洲和加勒比地区的新发艾滋病毒感染病例增加了13%，并归因于艾滋病毒预防药物使用方面的缺口。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nL4T45714A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","SG9999015952.SGD","IE00B7SZLL34.SGD","LU0122379950.USD","LU1934455277.USD","LU1037948541.HKD","LU0058720904.USD","LU0882574055.USD","IE00BKVL7J92.USD","SG9999015978.USD","LU1066051498.USD","TBXU","TMED","LU1430594728.SGD","LU1674673428.USD","GILD","LU1585245621.USD","LU0965509101.SGD","LU0965509283.SGD","IE0002270589.USD","LU0320765992.SGD","LU1066053197.SGD","LU2324357040.USD","LU0234570918.USD","LU1061106388.HKD","IE00B19Z3581.USD","LU0965509010.AUD","LU0859254822.USD","BK4139","LU0289739699.SGD","LU1037948897.HKD","BK4566","BMED","BK4588","BK4532","IBBQ","BK4568","LU0114720955.EUR","MEDI","IE00B19Z3B42.SGD","BK4550","LU0889565916.HKD","BBH","LU1057294990.SGD","LU1934455863.HKD","LU2112291526.USD","BIB","LU1674673691.USD","LU1839511570.USD","SG9999015945.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159280995","title":"吉利德科學攜手泛美衞生組織，加速拉美及加勒比地區HIV預防藥物Lenacapavir的可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=1159280995","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159280995?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:10","pubTimestamp":1789485009,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）日前宣布，与泛美卫生组织（PAHO）达成一项战略合作。此番联手，旨在显著提升一年两针的HIV预防药物Lenacapavir在拉丁美洲及加勒比地区的可及性。双方的合作，将为该区域的高风险人群带来更便捷的预防选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","BK4550","LU1057294990.SGD","SG9999015986.USD","GILD","LU1066053197.SGD","LU1839511570.USD","IE00BKVL7J92.USD","LU1778281490.HKD","IE00B7SZLL34.SGD","BK4139","LU0965509101.SGD","LU0058720904.USD","LU0122379950.USD","LU0889565916.HKD","LU1934455863.HKD","SG9999015978.USD","LU2468319806.SGD","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","LU1066051498.USD","IBBQ","BIB","LU0234570918.USD","LU1934455194.USD","IBB","LU2357627491.SGD","LU1061106388.HKD","LU1571399168.USD","BK4568","TMED","BK4585","SG9999015945.SGD","LU0861579265.USD","SG9999015952.SGD","IE0002270589.USD","LU1674673428.USD","IE00BZ1G4Q59.USD","MEDI","BK4583","BK4588","BK4532","BMED","LU1430594728.SGD","LU2112291526.USD","LU1585245621.USD","LU2089984988.USD","LU1023059063.AUD","TBXU","LU0859254822.USD","LU0109394709.USD","LU0114720955.EUR","BK4566","LU0320765992.SGD","LU0965508806.USD","LU1934455277.USD","LU2324357040.USD","LU1674673691.USD","LU0289739699.SGD","LU0823416689.USD","LU1037948897.HKD","LU2087621335.USD","LU0965509283.SGD","LU0965509010.AUD","LU1037948541.HKD","BK4578","IE00B19Z3581.USD","IE00B3T34201.USD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153389014","title":"吉利德高管表示，未來幾個季度HIV市場增長或將回歸2%-3%常態水平","url":"https://stock-news.laohu8.com/highlight/detail?id=1153389014","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153389014?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:09","pubTimestamp":1789484948,"startTime":"0","endTime":"0","summary":"吉利德高管在电话会议中透露，该公司预计HIV治疗市场的增长势头将在未来几个季度内逐步趋于稳定，最终回到2%至3%的年增长区间。这一表态正值市场对HIV药物需求持续波动的关键节点。高管指出，当前的增长水平仍高于长期趋势，但随着时间推移，这种偏热的状态将逐渐降温。整个行业的扩张速度，预计将在近期内回落至更为可持续的轨道上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673428.USD","LU1066053197.SGD","IE00B19Z3581.USD","LU0861579265.USD","LU1571399168.USD","LU1674673691.USD","SG9999015952.SGD","LU1430594728.SGD","IE00B7SZLL34.SGD","MEDI","IE00BSNM7G36.USD","LU1839511570.USD","IBBQ","TMED","LU1778281490.HKD","BK4583","IE00B19Z3B42.SGD","BBH","LU2468319806.SGD","TBXU","LU1057294990.SGD","IE00BZ1G4Q59.USD","LU0965509101.SGD","LU1061106388.HKD","LU1066051498.USD","LU0320765992.SGD","IBB","LU1037948541.HKD","BK4578","LU2112291526.USD","LU0058720904.USD","SG9999015978.USD","IE00BKVL7J92.USD","BK4566","BMED","LU0965508806.USD","LU0965509283.SGD","LU1023059063.AUD","LU1585245621.USD","LU1934455194.USD","LU0114720955.EUR","BIB","LU0859254822.USD","LU0889565916.HKD","LU0882574055.USD","BK4585","LU0965509010.AUD","BK4550","LU2089984988.USD","LU0122379950.USD","BK4139","BK4568","IE00B3T34201.USD","LU0109394709.USD","LU0234570918.USD","SG9999015986.USD","LU2357627491.SGD","LU1934455277.USD","LU1037948897.HKD","LU0289739699.SGD","LU2087621335.USD","LU1934455863.HKD","BK4532","LU2324357040.USD","LU0823416689.USD","IE0002270589.USD","GILD","SG9999015945.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131138631","title":"吉利德高管透露：周服HIV預防藥物有望2027年第一季度上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1131138631","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131138631?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:05","pubTimestamp":1789484737,"startTime":"0","endTime":"0","summary":"吉利德科学高管在电话会议中表示，其每周口服HIV预防药物预计将于2027年第一季度正式推出。这一表态为公司抗艾药物管线注入了新的期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","LU2324357040.USD","LU0114720955.EUR","MEDI","SG9999015978.USD","LU1430594728.SGD","BIB","IE00B19Z3581.USD","LU1839511570.USD","GILD","LU2089984988.USD","LU1037948541.HKD","LU0965509101.SGD","LU0289739699.SGD","LU2112291526.USD","BK4566","IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD","IBBQ","LU1037948897.HKD","BK4578","SG9999015986.USD","LU0965508806.USD","LU2468319806.SGD","LU2087621335.USD","LU2357627491.SGD","BK4139","LU1023059063.AUD","LU0320765992.SGD","LU0882574055.USD","LU1934455277.USD","LU0861579265.USD","IE00BSNM7G36.USD","LU1585245621.USD","LU0122379950.USD","LU0234570918.USD","LU1778281490.HKD","BK4568","LU0889565916.HKD","LU0058720904.USD","LU1674673691.USD","BK4550","LU1061106388.HKD","LU1571399168.USD","BMED","LU1066053197.SGD","IE00B3T34201.USD","IE0002270589.USD","BBH","IE00BKVL7J92.USD","LU1934455863.HKD","BK4585","TBXU","TMED","IE00B19Z3B42.SGD","LU0965509283.SGD","LU0109394709.USD","LU0823416689.USD","LU1057294990.SGD","LU0859254822.USD","SG9999015945.SGD","BK4588","LU1674673428.USD","LU1934455194.USD","IBB","BK4532","LU0965509010.AUD","SG9999015952.SGD","LU1066051498.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571008","title":"阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571008?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GNOM","SYNB","LU2322448791.USD","TMED","LFSC","HELX","LU1992135399.USD","PBE","BK4585","FTXH","BBH","CANC","LU2272731600.USD","LU2272731865.HKD","RSPH","PSCH","IBB","IDNA","IEIH","MRNY","XBIX","BK4588","FBT","BME","RXL","AZNH","LU2322448957.HKD","PJP","XPH","IEHS","LU2272731782.SGD","WDNA","IBRN","BIOY","LU2473716301.USD","IYH","MEDI","IE00B5TLWC47.USD","BBP","MRNX","LU1992135472.HKD","BIB","PPH","PBPH","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666528665","title":"又爆了！集體飆漲！中東，再傳重磅","url":"https://stock-news.laohu8.com/highlight/detail?id=2666528665","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666528665?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 11:37","pubTimestamp":1789011420,"startTime":"0","endTime":"0","summary":"中午好，在本周二大涨之后，能化板块又爆发了！周四早盘，原油期货主力合约一度涨近10%，纯苯、苯乙烯期货主力合约涨停。截至11:30收盘，原油期货主力合约涨幅有所收窄，纯苯期货主力合约涨 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260910/c679776426.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260910/c679776426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK4581","TBXU","IE00BFTCPJ56.SGD","LU1983299246.USD","BK4588","IE00B2B36J28.USD","LU1571399168.USD","BK4139","AMGN","LU2468319806.SGD","LU0868494617.USD","BK4566","LU1061106388.HKD","LU0058720904.USD","IBB","BK4585","LU0320765992.SGD","BIB","IE0009355771.USD","LU2112291526.USD","LU1057294990.SGD","IBBQ","IE0002141913.USD","PJP","BK4533","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4599","LU2089984988.USD","LU0122379950.USD","LU2242652126.USD","PBE","SG9999001440.SGD","LU0109394709.USD","LU2242646821.SGD","LU0289739699.SGD","IE00BJT1NW94.SGD","LU1023059063.AUD","BK4534","BBH","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666712586","title":"安進（AMGN）聯合療法III期臨床達主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2666712586","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666712586?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 16:59","pubTimestamp":1788944360,"startTime":"0","endTime":"0","summary":"金吾财经 | 安进公布，双特异性T细胞衔接器Imdelltra联合阿斯利康PD-L1抑制剂英飞凡，在广泛期小细胞肺癌的后期临床试验中实现总生存期延长。这家加州生物制药企业披露III期DeLLphi-305研究中期数据，该试验达成广泛期小细胞肺癌患者总生存期主要终点。该项全球试验评估该组合作为一线维持治疗，受试者既往接受过包含英飞凡的治疗且病情未发生进展。研究同时达成无进展生存期、客观缓解率两项次要终点。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305840","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","LU0029864427.USD","IE0002141913.USD","LU0289739699.SGD","BK4568","BK4585","BK4566","LU0128525929.USD","TBXU","LU1267930573.SGD","BBH","IE00B4R5TH58.HKD","LU2112291526.USD","LU2237443895.HKD","LU2089984988.USD","IE00BJJMRZ35.SGD","SG9999001440.SGD","BIB","LU2456880835.USD","LU0708994859.HKD","LU0058720904.USD","LU0868494617.USD","BK4599","BK4139","LU2242646821.SGD","LU2468319806.SGD","IBBQ","LU1829250122.USD","LU2237443382.USD","LU1023059063.AUD","LU2462157665.USD","PJP","BK4533","IE00BFTCPJ56.SGD","LU1571399168.USD","AZN","AZNH","LU0889565916.HKD","LU0122379950.USD","IBB","BK4534","LU0432979614.USD","LU2236285917.USD","LU2242652126.USD","PBE","IE00B2B36J28.USD","LU2237443622.USD","AMGN","LU2237443978.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666309213","title":"安進-阿斯利康肺癌聯合用藥在後期臨床試驗中顯著提升生存率","url":"https://stock-news.laohu8.com/highlight/detail?id=2666309213","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666309213?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 10:39","pubTimestamp":1788921579,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4534","BK4139","IE00B4R5TH58.HKD","PSYK","BK4599","LU1057294990.SGD","LU0058720904.USD","LU1023059063.AUD","LU0889565916.HKD","TBXU","AMGN","IE00B2B36J28.USD","LU2468319806.SGD","BK4585","PJP","SG9999001440.SGD","LU1983299246.USD","LU1571399168.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","MDTX","LU0868494617.USD","LU0320765992.SGD","BMED","PBE","BK4588","BIB","LU1061106388.HKD","IBBQ","IBBJ","BBH","LU0122379950.USD","IE0009355771.USD","IE00BJT1NW94.SGD","BK4566","LU2242652126.USD","IBB","IE00BJJMRZ35.SGD","BK4533","BK4581","LU2242646821.SGD","LU2112291526.USD","LU2089984988.USD","LU0289739699.SGD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112638879","title":"市場風向標：安進股價遭受重創","url":"https://stock-news.laohu8.com/highlight/detail?id=1112638879","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112638879?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 05:35","pubTimestamp":1788903338,"startTime":"0","endTime":"0","summary":"“这对安进而言，堪称最糟糕的结局。”——巴克莱分析师艾米丽·菲尔德如此评价。此前，诺华制药公布了其心脏病药物令人失望的试验结果，这一披露不仅让诺华自身承压，更给安进旗下一款重磅药物蒙上了厚厚的阴影。","market":"us","thumbnail":"https://static.tigerbbs.com/e5b05f9c7e258c0791b0ff14e4bfadad","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e5b05f9c7e258c0791b0ff14e4bfadad"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","PBE","LU0868494617.USD","BK4533","BK4581","LU0320765992.SGD","LU2089984988.USD","BBH","AMGN","LU0889565916.HKD","LU2468319806.SGD","IE00B2B36J28.USD","PJP","LU1057294990.SGD","BK4599","IE0009355771.USD","LU0122379950.USD","LU0109394709.USD","IBB","BK4139","IE00BFTCPJ56.SGD","LU0289739699.SGD","LU1983299246.USD","IE00BJJMRZ35.SGD","LU2242652126.USD","LU2112291526.USD","LU1023059063.AUD","LU1061106388.HKD","SG9999001440.SGD","BK4566","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","BK4585","BK4534","LU0058720904.USD","BIB","LU2242646821.SGD","BK4588","IBBQ","IE0002141913.USD","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136308873","title":"Assembly Biosciences有望獲得高達2.8億美元里程碑付款及美國境外特許權使用費","url":"https://stock-news.laohu8.com/highlight/detail?id=1136308873","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136308873?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:02","pubTimestamp":1788897732,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前披露，其在海外市场具备资格获取最高达2.8亿美元的里程碑款项，外加相应特许权使用费收入。据悉，这家生物科技企业所预期的资金流入将源自美国以外地区。对Assembly Biosciences而言，这笔潜在收入不仅反映其管线资产的外部合作价值，也可能为其后续研发投入提供坚实支撑。市场人士认为，此类非美国市场的收益结构有助于分散地域风险，增强公司财务韧性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1057294990.SGD","LU0965509283.SGD","IE00B7SZLL34.SGD","IBB","LU1585245621.USD","IE00B3T34201.USD","MEDI","BMED","LU0234570918.USD","LU1037948897.HKD","LU2089984988.USD","TMED","LU0289739699.SGD","LU1430594728.SGD","LU2087621335.USD","BK4588","LU2468319806.SGD","LU1778281490.HKD","SG9999015952.SGD","LU1037948541.HKD","SG9999015986.USD","ASMB","LU0122379950.USD","BK4583","BK4585","IE00BKVL7J92.USD","BK4532","BK4139","BBH","LU2112291526.USD","BIB","TBXU","LU0823416689.USD","LU1066051498.USD","LU0058720904.USD","IE00BSNM7G36.USD","LU0109394709.USD","LU1934455863.HKD","SG9999015978.USD","IBBQ","LU0965508806.USD","LU2324357040.USD","BK4550","BK4568","LU0965509101.SGD","IE00BZ1G4Q59.USD","SG9999015945.SGD","LU1674673691.USD","BK4578","LU0861579265.USD","IE0002270589.USD","LU1061106388.HKD","IE00B19Z3581.USD","LU0889565916.HKD","LU1066053197.SGD","LU0859254822.USD","LU1934455194.USD","LU2357627491.SGD","LU1023059063.AUD","LU1674673428.USD","LU0114720955.EUR","BK4566","LU0965509010.AUD","LU1934455277.USD","LU0882574055.USD","GILD","LU1571399168.USD","IE00B19Z3B42.SGD","LU0320765992.SGD","LU1839511570.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154623157","title":"Assembly Biosciences旗下Gs-1179預計2026年底前將推進至生殖器皰疹二期臨床試驗階段","url":"https://stock-news.laohu8.com/highlight/detail?id=1154623157","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154623157?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:02","pubTimestamp":1788897731,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前宣布，其研发管线中的候选药物Gs-1179有望在2026年年底之前顺利迈入针对生殖器疱疹的二期临床试验阶段。生殖器疱疹作为一种常见的性传播感染疾病，全球患者群体庞大，对创新疗法的需求十分迫切。Assembly Biosciences正积极加速该药物的研发进程，以期尽早为患者带来新的治疗选择。业内分析人士指出，若Gs-1179能够顺利通过后续试验的严格考验，将可能重塑该适应症的市场格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","LU2087621335.USD","LU1839511570.USD","BK4578","LU0289739699.SGD","IE00B19Z3B42.SGD","IBB","IE00B3T34201.USD","IE00BKVL7J92.USD","LU0882574055.USD","LU0058720904.USD","BMED","LU1585245621.USD","LU2112291526.USD","TMED","LU0859254822.USD","SG9999015978.USD","LU1066051498.USD","LU0965509010.AUD","LU1934455194.USD","GILD","LU0889565916.HKD","SG9999015986.USD","LU1061106388.HKD","LU0114720955.EUR","LU1934455863.HKD","LU1037948541.HKD","LU0320765992.SGD","BK4566","BK4550","BK4568","LU0861579265.USD","LU1674673691.USD","LU1023059063.AUD","SG9999015945.SGD","LU1057294990.SGD","SG9999015952.SGD","IBBQ","BIB","LU2357627491.SGD","LU1934455277.USD","TBXU","IE00B19Z3581.USD","LU0965509283.SGD","BK4532","LU0965508806.USD","LU1430594728.SGD","IE0002270589.USD","LU0109394709.USD","LU1571399168.USD","IE00B7SZLL34.SGD","LU2089984988.USD","BK4585","LU0234570918.USD","LU1066053197.SGD","IE00BZ1G4Q59.USD","LU1674673428.USD","BK4139","BK4583","ASMB","IE00BSNM7G36.USD","MEDI","LU2468319806.SGD","LU0122379950.USD","LU0823416689.USD","LU2324357040.USD","BK4588","LU1037948897.HKD","LU0965509101.SGD","LU1778281490.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115029168","title":"Assembly Biosciences：吉利德獨享HSV HPI項目臨床開發與商業化權利","url":"https://stock-news.laohu8.com/highlight/detail?id=1115029168","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115029168?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:01","pubTimestamp":1788897702,"startTime":"0","endTime":"0","summary":"Assembly Biosciences宣布，吉利德科学已保留其HSV HPI项目的独家临床开发及商业化权利。这一决定标志着双方合作进一步深化，吉利德将全权主导该项目的后续推进与市场布局。对于Assembly Biosciences而言，此举不仅明确了合作伙伴的战略优先级，也为其自身聚焦其他管线资源提供了更大灵活性。业内观察人士指出，HSV HPI项目的独家授权，反映了吉利德在抗病毒治疗领域持续加码的雄心，同时也凸显了该类创新疗法在未被满足的医疗需求中所蕴含的巨大潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4578","LU0109394709.USD","IBB","BK4139","LU0859254822.USD","LU2468319806.SGD","TBXU","IE00B19Z3B42.SGD","BK4532","LU0320765992.SGD","LU1839511570.USD","LU2112291526.USD","MEDI","IE0002270589.USD","BK4566","LU0114720955.EUR","IE00BSNM7G36.USD","LU0823416689.USD","LU1430594728.SGD","LU2089984988.USD","LU1934455194.USD","IE00BZ1G4Q59.USD","LU0965509010.AUD","LU1037948541.HKD","LU1585245621.USD","SG9999015945.SGD","LU0122379950.USD","LU1778281490.HKD","GILD","IE00B7SZLL34.SGD","BIB","LU2357627491.SGD","LU0965509101.SGD","LU0861579265.USD","LU0965508806.USD","SG9999015978.USD","LU2324357040.USD","LU1571399168.USD","LU1934455277.USD","LU1037948897.HKD","BK4588","SG9999015952.SGD","LU1061106388.HKD","LU1934455863.HKD","BK4583","LU2087621335.USD","BMED","BK4550","IBBQ","LU0058720904.USD","LU0234570918.USD","LU0965509283.SGD","BK4585","TMED","IE00BKVL7J92.USD","ASMB","LU0882574055.USD","LU0889565916.HKD","LU1023059063.AUD","IE00B19Z3581.USD","IE00B3T34201.USD","LU1066051498.USD","BK4568","LU1674673691.USD","SG9999015986.USD","BBH","LU1066053197.SGD","LU1057294990.SGD","LU0289739699.SGD","LU1674673428.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179230759","title":"Assembly Biosciences行使與吉利德關於HSV解旋酶-引物酶抑制劑項目的美國利潤分成選擇權","url":"https://stock-news.laohu8.com/highlight/detail?id=1179230759","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179230759?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:01","pubTimestamp":1788897669,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司已正式行使与吉利德科学就HSV解旋酶-引物酶抑制剂项目达成的美国利润分成选择权。这一战略举措标志着双方合作进入新阶段，有望加速该抗病毒疗法的临床开发与商业化进程。通过行使该选择权，Assembly Biosciences将能够分享该药物在美国市场的未来收益，同时借助吉利德在抗病毒领域的深厚积累与市场渠道，共同推进这一潜在重磅药物的落地。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","LU0823416689.USD","BBH","LU1066053197.SGD","LU0234570918.USD","LU1571399168.USD","LU1839511570.USD","LU1934455277.USD","LU0965509010.AUD","SG9999015945.SGD","IBB","BK4585","LU1934455863.HKD","IE0002270589.USD","LU1778281490.HKD","LU0889565916.HKD","LU1057294990.SGD","LU1430594728.SGD","LU1061106388.HKD","LU2468319806.SGD","MEDI","LU0114720955.EUR","BK4139","BMED","LU0965509101.SGD","IE00B19Z3581.USD","BK4583","BK4568","LU1066051498.USD","LU1674673428.USD","TBXU","TMED","LU0861579265.USD","LU0965508806.USD","SG9999015952.SGD","LU1585245621.USD","LU0289739699.SGD","IBBQ","LU0859254822.USD","SG9999015978.USD","GILD","IE00BKVL7J92.USD","BK4550","ASMB","LU0058720904.USD","SG9999015986.USD","LU0122379950.USD","BK4588","IE00BSNM7G36.USD","LU1674673691.USD","BK4566","LU0320765992.SGD","IE00B7SZLL34.SGD","LU1037948541.HKD","LU2089984988.USD","LU2324357040.USD","BIB","BK4578","IE00B19Z3B42.SGD","IE00B3T34201.USD","LU0109394709.USD","LU0882574055.USD","LU1934455194.USD","LU2087621335.USD","BK4532","LU2357627491.SGD","LU1037948897.HKD","LU2112291526.USD","IE00BZ1G4Q59.USD","LU0965509283.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":1,"totalSize":153,"code":"91000000","status":"200"}]}}